Latest market price
18.00
-0.44-2.39%
HQLQT61Tekla Life Sciences Investors·NYSE
18.00-2.39%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E2.73EPS (ttm)6.75Insider Own12.04%Shs Outstand30.41MPerf Week4.00%
Market Cap560.72MForward P/E—EPS next Y—Insider Trans0.01%Shs Float26.92MPerf Month1.49%
Enterprise Value559.72MPEG—EPS next Q—Short Float0.72%Perf Quarter-4.31%
Income198.00MP/S9.35EPS this Y—Short Ratio1.33Perf Half Y5.07%
Sales60.00MP/B1.00EPS next Y—ROA35.18%Short Interest192.66KPerf YTD9.89%
Book/sh18.45P/C—EPS next 5Y—ROE36.89%52W High22.67 -20.60%Perf Year5.43%
Cash/sh0.03P/FCF—EPS past 3/5Y— -10.52%ROIC35.24%52W Low15.66 14.94%Perf 3Y58.97%
Dividend Est.2.48 (13.78%)EV/EBITDA2.83Sales past 3/5Y39.03% 17.14%Gross Margin90.69%Volatility2.08% 2.85%Perf 5Y-11.90%
Dividend TTM2.24 (12.44%)EV/Sales9.33EPS Y/Y TTM—Oper. Margin—ATR (14)0.50Perf 10Y6.77%
Dividend Ex-DateAug 24, 2026Quick Ratio2.58Sales Y/Y TTM200.00%Profit Margin—RSI (14)53.02Recom—
Dividend Gr. 3/5Y10.20% 3.13%Current Ratio2.58EPS Q/Q—SMA204.07%Beta0.72Target Price—
Payout25.13%Debt/Eq0.00Sales Q/Q166.67%SMA50-3.50%Rel Volume0.65Prev Close18.44
Employees—LT Debt/Eq0.00Earnings—SMA2001.07%Avg Volume133.62KPrice18.00
IPO DateMay 01, 1992Option/ShortYes / YesEPS/Sales Surpr.—Net Debt/EBITDA-0.01Volume86,547Change-2.39%
Latest News· Times ET
Today
Oct-18-26
Sep-30-26
Sep-26-26
Sep-15-26
Aug-29-26
Aug-13-26
Jul-25-26
Jul-10-26
Jul-10-2609:07PM
Jul-03-26
Jul-03-2607:01AM
Company

Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
9/30/2025
FY 2024
9/30/2024
FY 2023
9/30/2023
FY 2022
9/30/2022
FY 2021
9/30/2021
FY 2020
9/30/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue60868739—————
Cost of Goods Sold Incl. D&A5555—————
Gross Profit54868718—————
Selling, General and Administrative Excl. Other4111—————
Research and Development
0000—————
Other Operating Expense
-148000—————
Operating Income1988685-5—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)00028—————
Net Income Before Taxes198868522—————
Income Taxes
0000—————
Consolidated Net Income198868522—————
Net Income From Continuing Operations198868522—————
Net Income198868522—————
EPS (Recurring)6.752.963.040.79—————
EPS (Basic, Before Extraordinaries)6.752.963.040.79—————
EPS (Diluted)6.752.963.040.79—————
EBITDA198868725—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio2.675.244.9615.78—————
Price To Sales Ratio9.005.234.858.95—————
Gross Margin90.00100.00100.0046.15—————
Operating Margin330.00100.0097.70-12.82—————
Net Margin330.00100.0097.7056.41—————
Shares Outstanding30292828—————
Market Capitalization540450422349—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$24.03$21.09$18.15$15.21$12.27● Close Price0.00K33.44K66.88K100.32K133.75KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Mahai Chris LaVictoireDirectorJul 16 '26Buy19.9252710,498527Jul 20
Pittard ChristianDirectorDec 16 '25Buy16.887,923133,7557,923Dec 18
Saba Capital Management, L.P.10% OwnerSep 22 '25Sale14.1441,623588,5492,837,633Sep 23
Saba Capital Management, L.P.10% OwnerSep 19 '25Sale14.106,98998,5452,879,256Sep 23
Saba Capital Management, L.P.10% OwnerSep 18 '25Sale14.0740,208565,7272,886,245Sep 19
Saba Capital Management, L.P.10% OwnerSep 17 '25Sale13.9924,328340,3492,926,453Sep 19
Saba Capital Management, L.P.10% OwnerSep 16 '25Sale13.992,02628,3442,950,781Sep 17
Saba Capital Management, L.P.10% OwnerSep 15 '25Sale14.137009,8912,952,807Sep 17
Saba Capital Management, L.P.10% OwnerSep 11 '25Sale14.2815,116215,8562,953,507Sep 15
Saba Capital Management, L.P.10% OwnerSep 02 '25Sale14.0414,083197,7252,968,623Sep 04
Saba Capital Management, L.P.10% OwnerAug 29 '25Sale13.8923,723329,5122,982,706Sep 02
Saba Capital Management, L.P.10% OwnerAug 26 '25Sale13.834005,5323,006,429Aug 27
Saba Capital Management, L.P.10% OwnerAug 21 '25Sale14.0710,710150,6903,006,829Aug 25
Saba Capital Management, L.P.10% OwnerMay 20 '25Sale12.7111,419145,1353,017,539May 22
Saba Capital Management, L.P.10% OwnerMay 15 '25Sale12.0823,729286,6463,028,958May 19
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.